Moody Aldrich Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,863
| Closed | -$671K | – | 224 |
|
|
2024
Q1 | $671K | Hold |
4,863
| – | – | 0.11% | 127 |
|
|
2023
Q4 | $641K | Hold |
4,863
| – | – | 0.12% | 125 |
|
|
2023
Q3 | $547K | Buy |
+4,863
| New | +$547K | 0.1% | 127 |
|
|
2020
Q3 | – | Sell |
-1,683
| Closed | -$205K | – | 177 |
|
|
2020
Q2 | $205K | Buy |
+1,683
| New | +$205K | 0.04% | 157 |
|
|
2018
Q4 | – | Sell |
-1,725
| Closed | -$212K | – | 105 |
|
|
2018
Q3 | $212K | Buy |
+1,725
| New | +$212K | 0.06% | 102 |
|
|
2018
Q1 | – | Sell |
-2,702
| Closed | -$210K | – | 94 |
|
|
2017
Q4 | $210K | Sell |
2,702
-19,554
| -88% | -$1.52M | 0.17% | 88 |
|
|
2017
Q3 | $1.36M | Buy |
22,256
+2,591
| +13% | +$159K | 1.4% | 25 |
|
|
2017
Q2 | $905K | Buy |
19,665
+10,515
| +115% | +$484K | 1.13% | 36 |
|
|
2017
Q1 | $396K | Sell |
9,150
-15,245
| -62% | -$660K | 0.68% | 70 |
|
|
2016
Q4 | $944K | Sell |
24,395
-9,945
| -29% | -$385K | 0.61% | 70 |
|
|
2016
Q3 | $1.74M | Buy |
34,340
+3,380
| +11% | +$171K | 1.21% | 30 |
|
|
2016
Q2 | $1.41M | Buy |
30,960
+21,125
| +215% | +$960K | 1.16% | 33 |
|
|
2016
Q1 | $389K | Buy |
+9,835
| New | +$389K | 0.82% | 70 |
|